• Explore /
  • Poster
  • / Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC.

Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC.

Abstract Poster

Authors

Paul Baas

Paul Baas

Netherlands Cancer Institute, Amsterdam, Netherlands

Paul Baas , Edward B. Garon , Roy S. Herbst , Enriqueta Felip , Jose Luis Perez-Gracia , Ji-Youn Han , Julian R. Molina , Joo-Hang Kim , Catherine Dubos Arvis , Myung-Ju Ahn , Margarita Majem , Mary J. Fidler , Fabrice Barlesi , Gilberto Castro Jr., Marcelo Garrido , Yue Shentu , Gregory M. Lubiniecki , Ellie Im , Dong-Wan Kim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01905657

Citation

J Clin Oncol 34, 2016 (suppl; abstr 9015)

DOI

10.1200/JCO.2016.34.15_suppl.9015

Abstract #

9015

Poster Bd #

338

Abstract Disclosures

Similar Posters

First Author: Roy S. Herbst

First Author: Biagio Ricciuti

First Author: Nikhil Shukla

First Author: Hiroshi Takumida